- Engage with senior executives from prominent life sciences companies, CROs and healthcare providers
- 75% of attendees in 2023 had a job title of 'Head of' or above, so true decision-makers will be on site
- Schedule 1-to-1 meetings with leaders in the online event community
- Establish new relationships and strengthen ties at our evening drinks reception
- FT editors and other global press outlets will be there
The Financial Times US Pharma and Biotech Summit will be returning to New York in May 2025, partnered with Endpoints News for the second year. The event will gather biopharma leaders, regulators, investors and scientists to share unique insights about the year ahead and discuss the most important trends affecting the industry, and the country.
Join us to learn how the new market cycle will finance the next period of investing in innovation. Debate the dueling approaches to the US life expectancy crisis. Hear how artificial intelligence is splitting into two technological camps. And learn how drug makers, tech startups and insurers are fighting it out to redefine their relationship with patients.
.jpg)
THE SUPER EARLY BIRD
IN-PERSON PASS
Gain access to in-person sessions and networking drinks. Network and connect with your peers.
$1,769
Full price $2,589 from 10th March 2025
Why Attend?
Learn
how America's life sciences landscape is evolving in areas such as innovation, commercialization and regulation
Engage
with C-suite executives responsible for the big decisions in areas such as funding, workforce development and strategic partnerships
Enjoy
the opportunity to network with peers and build relationships in a friendly but focused environment
The power of in-person networking
"An incredibly well-curated event. A great combination of thought-provoking discussions and networking." Previous attendee
Contact us
Speaking Opportunities
Ciaran Larkin
ciaran.larkin@ft.com
Sponsorship
Holly Watson-Steward
holly.watson-steward@ft.com
Delegate Services
Hauwra Sharif
hauwra.sharif@ft.com
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice
